Mazdutide 6mg
Dual GLP-1/Glucagon Agonist for Next-Generation Metabolic Research
Mazdutide is a dual GLP-1/glucagon receptor agonist developed in China showing significant weight loss and NASH improvement in Phase 2/3 trials, representing an alternative dual-mechanism approach to Retatrutide.
Dual GLP-1/Glucagon Agonist for Next-Generation Metabolic Research
Mazdutide (IBI362) activates GLP-1R for appetite suppression and GCGR for increased energy expenditure and hepatic fat clearance, producing robust weight loss and liver health improvements in clinical studies.
As one of the most studied compounds in the metabolic & fat loss research space, Mazdutide has attracted sustained scientific interest across Dual incretin/glucagon research, NASH and fatty liver studies, Next-generation obesity research. Peer-reviewed evidence indicates that phase 2/3 data showing significant weight loss, which has positioned Mazdutide as a reference standard for researchers exploring dual incretin/glucagon research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Mazdutide Documented Benefits: 2 Documented Mechanisms
Dual GLP-1/Glucagon Mechanism
Combines appetite suppression (GLP-1R) with energy expenditure increase (GCGR) for synergistic weight loss.
NASH Treatment Potential
Glucagon receptor activity drives hepatic fat oxidation showing promise for fatty liver disease treatment.
How Mazdutide Works: Molecular Mechanism & Pathway
Dual GLP-1R/GCGR agonist leveraging complementary incretin and glucagon pathways for weight loss and hepatic fat clearance.
The 2 primary research pathways identified for Mazdutide — Dual GLP-1/Glucagon Mechanism, NASH Treatment Potential — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that nASH improvement alongside weight reduction, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Mazdutide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Mazdutide is routinely studied alongside Tirzepatide and Retatrutide in metabolic & fat loss-focused compound panels. Researchers investigating dual incretin/glucagon research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that alternative dual mechanism to semaglutide+glucagon has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Mazdutide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2/3 data showing significant weight loss
- NASH improvement alongside weight reduction
- Alternative dual mechanism to semaglutide+glucagon
Ideal For
- Dual incretin/glucagon research
- NASH and fatty liver studies
- Next-generation obesity research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Mazdutide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2/3 data showing significant weight loss
NASH improvement alongside weight reduction
Alternative dual mechanism to semaglutide+glucagon
Third-Party Verified Every Batch
Each vial of Mazdutide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
